Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas

World Journal of Surgical Oncology

Volumn 8, Issue , 2010, Pages

  Bao, Guoqiang ^a   Qiao, Qing ^a   Zhao, Huadong ^a   He, Xianli ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN;

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; ADENOCARCINOMA; AGED; DISEASE COURSE; ENZYME IMMUNOASSAY; LYMPH NODE METASTASIS; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; STOMACH TUMOR; SURVIVAL RATE; TISSUE MICROARRAY;

ADENOCARCINOMA; AGED; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HMGB1 PROTEIN; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS;

EID: 77953818716     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-8-52     Document Type: Article

References (31)

1. Meyer A, Staratschek-Jox A, Springwald A, Wenk H, Wolf J, Wickenhauser C, Bullerdiek J. Non-Hodgkin lymphoma expressing high levels of the danger-signalling protein HMGB1. Leuk Lymphoma 2008, 49:1184-9. 10.1080/10428190802064909, 18569640.
2. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248-51. 10.1126/science.285.5425.248, 10398600.
3. Lange SS, Mitchell DL, Vasquez KM. High mobility group protein B1 enhances DNA repair and chromatin modification after DNA damage. Proc Natl Acad Sci USA 2008, 105:10320-5. 10.1073/pnas.0803181105, 2492475, 18650382.
4. Mollnes TE. High mobility group box-1 protein - one step closer to the clinic?. Crit Care 2008, 12:168. 10.1186/cc6944, 18671827.
5. Coffelt SB, Scandurro AB. Tumors sound the alarmin(s). Cancer Res 2008, 68:6482-5. 10.1158/0008-5472.CAN-08-0044, 2755533, 18701469.
6. Bartling B, Fuchs C, Silber RE, Simm A. Fibroblasts mediate induction of high mobility group box protein 1 in lung epithelial cancer cells by diffusible factors. Int J Mol Med 2007, 20:217-24.
7. van Beijnum JR, Buurman WA, Griffioen AW. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 2008, 11:91-9. 10.1007/s10456-008-9093-5, 18264787.
8. Campana L, Bosurgi L, Rovere-Querini P. HMGB1: a two-headed signal regulating tumor progression and immunity. Curr Opin Immunol 2008, 20:518-23. 10.1016/j.coi.2008.04.012, 18599281.
9. Hagemann T, Balkwill F, Lawrence T. Inflammation and cancer: a double-edged sword. Cancer Cell 2007, 12:300-1. 10.1016/j.ccr.2007.10.005, 2592547, 17936555.
10. Apetoh L, Tesniere A, Ghiringhelli F, Kroemer G, Zitvogel L. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res 2008, 68:4026-30. 10.1158/0008-5472.CAN-08-0427, 18519658.
11. Dong Xda E, Ito N, Lotze MT, Demarco RA, Popovic P, Shand SH, Watkins S, Winikoff S, Brown CK, Bartlett DL, Zeh HJ. High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother 2007, 30:596-606. 10.1097/CJI.0b013e31804efc76, 17667523.
12. Rauvala H, Rouhiainen A. RAGE as a receptor of HMGB1 (Amphoterin): roles in health and disease. Curr Mol Med 2007, 7:725-34. 10.2174/156652407783220750, 18331230.
13. Mollnes TE. High mobility group box-1 protein--one step closer to the clinic?. Crit Care 2008, 12:168. 10.1186/cc6944, 2575561, 18671827.
14. Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A, Lotze MT. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res 2007, 13:2836-48. 10.1158/1078-0432.CCR-06-1953, 17504981.
15. Allmen EU, Koch M, Fritz G, Legler DF. V domain of RAGE interacts with AGEs on prostate carcinoma cells. Prostate 2008, 68:748-58. 10.1002/pros.20736, 18302220.
16. Tang D, Kang R, Zeh HJ, Lotze MT. High-mobility group box 1 and cancer. Biochimica et Biophysica Acta 2010, 1799:131-40.
17. Moriwaka Y, Luo Y, Ohmori H, Fujii K, Tatsumoto N, Sasahira T, Kuniyasu H. HMGB1 attenuates anti-metastatic defense of the lymph nodes in colorectal cancer. Pathobiology 2010, 77(1):17-23. 10.1159/000272950, 20185963.
18. Kuniyasu H, Yano S, Sasaki T, Sasahira T, Sone S, Ohmori H. Colon cancer cell-derived high mobility group 1/amphoterin induces growth inhibition and apoptosis in macrophages. Am J Pathol 2005, 166:751-60. 1602344, 15743787.
19. Logsdon CD, Fuentes MK, Huang EH, Arumugam T. RAGE and RAGE ligands in cancer. Curr Mol Med 2007, 7:777-89. 10.2174/156652407783220697, 18331236.
20. Lotze MT, DeMarco RA. Dealing with death: HMGB1 as a novel target for cancer therapy. Curr Opin Investig Drugs 2003, 4:1405-9.
21. Jiao Y, Wang HC, Fan SJ. Growth suppression and radiosensitivity increase by HMGB1 in breast cancer. Acta Pharmacol Sin 2007, 28:1957-67. 10.1111/j.1745-7254.2007.00669.x, 18031610.
22. Riuzzi F, Sorci G, Donato R. RAGE expression in rhabdomyosarcoma cells results in myogenic differentiation and reduced proliferation, migration, invasiveness, and tumor growth. Am J Pathol 2007, 171:947-61. 10.2353/ajpath.2007.070049, 1959489, 17640970.
23. Ditsworth D, Zong WX, Thompson CB. Activation of poly(ADP)-ribose polymerase (PARP-1) induces release of the pro-inflammatory mediator HMGB1 from the nucleus. J Biol Chem 2007, 282:17845-54. 10.1074/jbc.M701465200, 17430886.
24. Apetoh L, Mignot G, Panaretakis T, Kroemer G, Zitvogel L. Immunogenicity of anthracyclines: moving towards more personalized medicine. Trends Mol Med 2008, 14:141-51. 10.1016/j.molmed.2008.02.002, 18353726.
25. Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, Mariette C, Chaput N, Mira JP, Delaloge S, André F, Tursz T, Kroemer G, Zitvogel L. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007, 220:47-59. 10.1111/j.1600-065X.2007.00573.x, 17979839.
26. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, André F, Delaloge S, Tursz T, Kroemer G, Zitvogel L. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007, 13:1050-9. 10.1038/nm1622, 17704786.
27. Cheng BQ, Jia CQ, Liu CT, Lu XF, Zhong N, Zhang ZL, Fan W, Li YQ. Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig Liver Dis 2008, 40:446-52. 10.1016/j.dld.2007.11.024, 18294942.
28. Chung HW, Lee SG, Kim H, Hong DJ, Chung JB, Stroncek D, Lim JB. Serum high mobility group box-1(HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl med 2009, 7:38. 10.1186/1479-5876-7-38, 2694170, 19476625.
29. Akaike H, Kono K, Sugai H, Takahashi A, Mimura K, Kawaguchi Y, Fujii H. Expression of high mobility group box chromosomal protein-1 (HMGB-1) in gastric cancer. Anticancer Res 2007, 27:449-57.
30. Völp K, Brezniceanu ML, Bösser S, Brabletz T, Kirchner T, Göttel D, Joos S, Zörnig M. Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut 2006, 55:234-42. 10.1136/gut.2004.062729, 1856519, 16118352.
31. Yao X, Zhao G, Yang H, Hong X, Bie L, Liu G. Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma. J Cancer Res Clin Oncol 2010, 136:677-84. 10.1007/s00432-009-0706-1, 19898867.